AcelRx Pharmaceuticals
2005
FOUNDED
PUBLIC
STATUS
81-90
EMPLOYEES
ACRX
STOCK SYMBOL
$1.84
SHARE PRICE
(As of Wednesday Closing)
Description
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.
Website
Formerly Known As
Surx
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Therapeutic Devices
Stock Exchange
NAS
Primary Office
- 351 Galveston Drive
- Redwood City, CA 94063
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore AcelRx Pharmaceuticals’s full profile, request a free trial.
AcelRx Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $1.64 - $4.09 | $146M | $1.80 | -$0.67 | 865K | 79.6M |
AcelRx Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 111,980 | 127,052 | 56,404 | 46,731 |
| Revenue | 2,427 | 2,151 | 7,995 | 17,357 |
| EBITDA | (48,897) | (35,152) | (36,938) | (29,905) |
| Net Income | (51,375) | (47,149) | (51,508) | (43,157) |
| Total Assets | 104,978 | 120,533 | 75,552 | 99,993 |
| Total Debt | 28,841 | 11,991 | 19,096 | 21,549 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
AcelRx Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore AcelRx Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookAcelRx Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore AcelRx Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookAcelRx Pharmaceuticals Competitors (21)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evoke Pharma | Formerly VC-backed | Solana Beach, CA | 0 | 0000 | 00000000000 | 0000 |
| 00000 000000000000 | Formerly VC-backed | Bridgewater, NJ | 0000 | 00000 | 000000&0 | |
| 00000000 | Venture Capital-Backed | San Francisco, CA | 0000 | 00000000000 | 0000 | |
| 000000 | Formerly VC-backed | Mountain View, CA | 00 | 00000 | 000000&0 | 00000 |
| 000000 | Corporation | North Chicago, IL | 000000 | 000.00 | 000000000 | 000.00 |
AcelRx Pharmaceuticals Executive Team (18)
10 Former Executives
You’re viewing 5 of 18 executives. Get the full list »AcelRx Pharmaceuticals Board Members (11)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Adrian Adams | Self | Chairman & Board Member | 000 0000 | |
| Howard Rosen | AcelRx Pharmaceuticals | Board Member | 000 0000 | |
| Mark Edwards | Self | Board Member | 000 0000 | |
| Mark Wan | Three Arch Partners | Board Member | 000 0000 | |
| Richard Afable MD | Self | Board Member | 000 0000 |
4 Former Board Members
You’re viewing 5 of 11 board members. Get the full list »